Navigation Links
Higher Plavix Dose Won't Boost Outcomes After Stent Placement: Study
Date:11/17/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, Nov. 16 (HealthDay News) -- Higher doses of the blood-thinner Plavix were no better at preventing heart attacks, blood clots or death than the standard lower dose in patients who had received artery-opening stents, new research shows.

The higher dose -- double the usual amount -- was tested in patients with "high platelet reactivity," meaning they failed to respond to the drug at lower doses.

Plavix (clopidogrel) helps prevent clots from forming in patients who have low platelet reactivity and who have had stents inserted to prop open blocked arteries.

But the new study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to study lead author Dr. Matthew Price, who presented the findings Tuesday at the annual meeting of the American Heart Association in Chicago.

So, the study leaves an important question unanswered: How to treat heart patients who don't respond well to Plavix?

"It remains uncertain to some extent," said Dr. Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an important study to have done but the key issues are that a significant proportion of the patients remained with high platelet reactivity even after being on the higher dose."

Previous, smaller studies had indicated that Plavix might have more of an effect if the dose was doubled.

"Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a high reactivity level is associated with poorer outcomes after angioplasty and/or stenting. But until now, a steep rise in the dose of Plavix "has not been tested in a large randomized clinical trial," he said.

For this trial, investigators tested a large group of patients for platelet reactivity after they had undergone angioplasty to place a drug-eluting stent. Drug-eluting stents emit medicines that help ward off vessel re-closure.

Over 2,200 patients with high platelet reactivity were then randomized to receive 150 milligrams a day of Plavix or the standard 75-milligram dose.

After six months, 2.3 percent of those taking either the higher or the lower dose suffered heart attacks, experienced blood clots in their stents, or died, the researchers report.

Those taking the higher dose of the blood-thinner didn't have any worse bleeding than those taking the standard dose, indicating that the higher dose of Plavix in this group of patients wasn't any less safe.

The study was sponsored by Accumetrics, which makes VerifyNow, a test used to measure platelet function. The makers of Plavix, Sanofi-Aventis and Bristol-Myers Squibb provided the drug, and lead investigator Price also disclosed ties with pharmaceutical companies.

"The trial does not support a treatment strategy of high dose clopidogrel in . . . patients with high-risk reactivity identified by a single platelet test," Price said.

Still, Prasad said that higher risk patient populations may need to be studied before drawing any firm conclusions about dosing. "Or maybe we need a more potent drug," he said.

More information

For more on stents, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Abhiram Prasad, M.D., interventional cardiologist, Mayo Clinic, Rochester, Minn.; American Heart Association annual meeting news conference with Matthew J. Price, M.D., director, Cardiac Catheterization Laboratory, Scripps Clinic and assistant professor, Scripps Translational Science Institute, La Jolla, Calif., Nov. 16, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Prostate cancer treatment linked to higher rate of colon cancer, study finds
2. Higher Statin Doses Linked to Fewer Heart Attacks, Stroke
3. Higher medication spending doesnt indicate better prescribing quality
4. Many Higher-Income Parents Forgoing Kids Vaccinations: Report
5. Organic onions, carrots and potatoes do not have higher levels of healthful antioxidants
6. Concussion Rate in Young Hockey Players Higher Than Thought
7. Shift work linked to higher risk of work injury: UBC study
8. Elderly women at higher risk for unnecessary urinary catheterization, study reports
9. Children with ADHD Symptoms at Higher Risk of Obesity
10. Brain Deficits Higher in Seniors Who Survive Blood Poisoning
11. GI Endoscopy Complication Rates Higher Than Suspected: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Higher Plavix Dose Won't Boost Outcomes After Stent Placement: Study
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home ... as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its ... bookmark and read organized content on topics such as home care (generally) as well ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, ... based in Denver, Colorado, announced an agreement to create the Jane and Leonard ... of the Jane and Leonard Korman Family Foundation. The collaboration leverages the strengths ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology: